Close Menu

NEW YORK (GenomeWeb) – Biodesix said today that it has acquired Seattle-based Integrated Diagnostics.

Financial terms of the deal were not disclosed.

The acquisition adds Indi's XL2 lung cancer test to Biodesix's portfolio. A second generation technology of what was previously called Xpresys Lung, the XL2 test measures two protein markers in the blood, which, combined with other pathologic and clinical factors, can improve the identification of cancers in individuals who have had a lung nodule detected via imaging.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.